Cardiac Rehabilitation to Improve Breast Cancer Outcomes (CRIBCO)
Cardiac Rehabilitation to Improve Breast Cancer Outcomes (CRIBCO)
Sponsor: University of Michigan Rogel Cancer Center
Terminated
Insufficient Budget
Other terminated trials from University of Michigan Rogel Cancer Center
- Biliary Tract Cancer · Phase PHASE1/PHASE2 · Apr 2024
- Gynecologic Cancer · Phase PHASE3 · Mar 2024
- Renal Cell Carcinoma, Metastatic · Phase PHASE2 · Oct 2022
- Non-small Cell Lung Cancer · Phase PHASE2 · Nov 2021
- Head and Neck Cancer · Phase PHASE2 · Dec 2020
See all terminations from University of Michigan Rogel Cancer Center
This NA trial investigates Breast Cancer and Cardiovascular Diseases and is currently terminated or withdrawn. University of Michigan Rogel Cancer Center leads this study, which shows 9 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
May 2025 — Present [monthly]
Terminated NA
Status: Suspended → Terminated
-
Jan 2025 — May 2025 [monthly]
Suspended NA
Status: Recruiting → Suspended
-
Sep 2024 — Jan 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Apr 2024 — Jul 2024 [monthly]
Recruiting NA
▶ Show 4 earlier versions
-
Feb 2024 — Apr 2024 [monthly]
Recruiting NA
-
Dec 2023 — Feb 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Sep 2023 — Dec 2023 [monthly]
Not Yet Recruiting NA
-
Jun 2023 — Sep 2023 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Michigan Rogel Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .